Key facts
- It has raised $316.7M across 4 recorded rounds; the latest was Early Stage VC ($7.2M) in Aug 2022.
- Notable investors include Partners Investment, AFW Partners, Shinhan Securities, IBK Capital, Medici Investment — 12 tracked in total.
- Cerecin has filed 4 Form Ds with the SEC since 2021, most recently Jun 2024 ($3.7M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Cerecin
Funding rounds
4 roundsAbout Cerecin
Developer of therapeutics technology designed to treat memory impairment and other neurodegenerative diseases. The company offers lipid science to explore the potential therapeutic benefits of medium-chain triglycerides which are designed to induce ketosis and improve mitochondrial metabolism and develops novel evidence-based alternatives that help people, pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, enabling clinicians to have access to brain health-focused products and therapies to treat diseases of the brain.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2000
- Employees
- 38
- Website
- cerecin.com/
- Ownership
- Privately Held (backing)
Cerecin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cerecin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cerecin in its N-PORT filings yet. We sweep new filings monthly.